Status of PCSK9 Monoclonal Antibodies in Australia

Daniel J. Scherer; Adam J. Nelson; Richard O'Brien; Karam M. Kostner; David L. Hare; David M. Colquhoun; Philip J. Barter; Philip Aylward; Stephen J. Nicholls; Gerald F. Watts

doi:10.1016/j.hlc.2019.04.014

Status of PCSK9 Monoclonal Antibodies in Australia

Daniel J. Scherer, Adam J. Nelson, Richard O'Brien, Karam M. Kostner, David L. Hare, David M. Colquhoun, Philip J. Barter, Philip Aylward, Stephen J. Nicholls, Gerald F. Watts

College of Medicine and Public Health

Research output: Contribution to journal › Review article › peer-review

8 Citations (Scopus)

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage. This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy.

Original language	English
Pages (from-to)	1571-1579
Number of pages	9
Journal	Heart, Lung and Circulation
Volume	28
Issue number	10
DOIs	https://doi.org/10.1016/j.hlc.2019.04.014
Publication status	Published - Oct 2019

Keywords

Atherosclerosis
Cardiovascular risk
Lipids
PCSK9 inhibitors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.hlc.2019.04.014Licence: In Copyright

Cite this

@article{5e5abf4fcbe94e7eb32f735162a0d5cb,

title = "Status of PCSK9 Monoclonal Antibodies in Australia",

abstract = "Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage. This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy.",

keywords = "Atherosclerosis, Cardiovascular risk, Lipids, PCSK9 inhibitors",

author = "Scherer, {Daniel J.} and Nelson, {Adam J.} and Richard O'Brien and Kostner, {Karam M.} and Hare, {David L.} and Colquhoun, {David M.} and Barter, {Philip J.} and Philip Aylward and Nicholls, {Stephen J.} and Watts, {Gerald F.}",

year = "2019",

month = oct,

doi = "10.1016/j.hlc.2019.04.014",

language = "English",

volume = "28",

pages = "1571--1579",

journal = "Heart, Lung and Circulation",

issn = "1443-9506",

publisher = "Elsevier Australia",

number = "10",

}

TY - JOUR

T1 - Status of PCSK9 Monoclonal Antibodies in Australia

AU - Scherer, Daniel J.

AU - Nelson, Adam J.

AU - O'Brien, Richard

AU - Kostner, Karam M.

AU - Hare, David L.

AU - Colquhoun, David M.

AU - Barter, Philip J.

AU - Aylward, Philip

AU - Nicholls, Stephen J.

AU - Watts, Gerald F.

PY - 2019/10

Y1 - 2019/10

N2 - Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage. This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy.

AB - Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage. This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy.

KW - Atherosclerosis

KW - Cardiovascular risk

KW - Lipids

KW - PCSK9 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85065569958&partnerID=8YFLogxK

U2 - 10.1016/j.hlc.2019.04.014

DO - 10.1016/j.hlc.2019.04.014

M3 - Review article

C2 - 31104887

AN - SCOPUS:85065569958

SN - 1443-9506

VL - 28

SP - 1571

EP - 1579

JO - Heart, Lung and Circulation

JF - Heart, Lung and Circulation

IS - 10

ER -

Status of PCSK9 Monoclonal Antibodies in Australia

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this